Traws Pharma, Inc. (TRAW)
(Real Time Quote from BATS)
$0.37 USD
+0.03 (7.84%)
Updated Aug 15, 2024 03:06 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Traws Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 21 | 20 | 17 | 25 | 24 |
Income After Depreciation & Amortization | -20 | -20 | -17 | -25 | -22 |
Non-Operating Income | 1 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -19 | -19 | -16 | -25 | -21 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -19 | -19 | -16 | -25 | -22 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -19 | -19 | -16 | -25 | -22 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -20 | -20 | -16 | -25 | -22 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -20 | -20 | -17 | -25 | -22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 20.99 | 20.91 | 16.83 | 11.61 | 0.96 |
Diluted EPS Before Non-Recurring Items | -0.90 | -0.91 | -0.96 | -2.10 | -22.34 |
Diluted Net EPS (GAAP) | -0.90 | -0.91 | -0.96 | -2.10 | -22.34 |
Fiscal Year end for Traws Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.06 | 0.06 | 0.06 | 0.06 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.06 | 0.06 | 0.06 | 0.06 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.27 | 4.51 | 5.15 | 4.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5.21 | -4.45 | -5.09 | -4.61 |
Non-Operating Income | NA | 0.23 | 0.28 | 0.35 | 0.36 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -4.98 | -4.18 | -4.74 | -4.25 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.98 | -4.18 | -4.74 | -4.25 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.98 | -4.18 | -4.74 | -4.25 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 21.04 | 20.99 | 21.00 | 20.98 |
Diluted EPS Before Non-Recurring Items | NA | -0.24 | -0.20 | -0.23 | -0.20 |
Diluted Net EPS (GAAP) | NA | -0.24 | -0.19 | -0.23 | -0.20 |